Market Newsdesk

SAN FRANCISCO, Jan. 13, 2021 (GLOBE NEWSWIRE) — pMD^®, the innovation leader in health care technology, has been honored with a Glassdoor Employees’ Choice Award in the U.S. small and medium company category, recognizing the Best Places to Work in the United States in 2021. The Employees’ Choice Award, now in its 13th year, is based solely on the input of employees, who elect to provide anonymous feedback by completing a company review about their job, work environment and employer on Glassdoor, the worldwide leader on insights about jobs and companies.

“Our mission at pMD is to improve patient outcomes, and that process begins with supporting our dedicated and passionate employees,” said Philippe d’Offay, founder and CEO of pMD. “We’ve learned over the last two decades that when employees feel cared for, this sentiment reflects back into their work and, in turn, positively impacts the health care community. In order to ensure our employees reach their personal and professional goals, we have placed an emphasis on providing a collaborative work environment with a dynamic mentorship program and easy access to leadership.”

The health care industry is undergoing rapid change at the moment with the demand for telehealth playing a key role in reshaping how care is delivered. pMD was founded with the mission to reduce medical errors and save patient lives; and in the midst of a global health crisis, the company finds itself able to do just that by offering a combination of software and services that makes it easy for teams to provide the best possible care, whether in-person or virtual.

“COVID-19 is in the driver’s seat and every employer has been impacted. This year’s winning employers have proven, according to employees, that even during extraordinary times, they’ll rise to the challenge to support their people,” said Christian Sutherland-Wong, Glassdoor chief executive officer. “A mission-driven culture, transparent leadership and career opportunities are always hallmarks of Best Places to Work winners. This year, we also see exceptional employers who have prioritized the health, safety and well-being of their employees. My congratulations go to all of this year’s outstanding Employees’ Choice Award winners.”

Glassdoor’s Best Places to Work were determined using company reviews shared by U.S.-based employees. To be considered for the U.S. small and medium company category, a company must have had fewer than 1,000 employees and have received at least 30 ratings across each of the eight workplace attributes (overall company rating, career opportunities, compensation and benefits, culture and values, senior management, work-life balance, recommend to a friend and six-month business outlook) during the period of eligibility. Current and former employees voluntarily and anonymously share insights and opinions about their work environments by sharing a company review, designed to capture a genuine and authentic inside look at what a specific job may be like at a particular company. In addition, employees are asked to describe the best reasons to work at their companies as well as any downsides.

For the complete list of the Glassdoor Best Places to Work winners in 2021, please visit: https://www.glassdoor.com/Award/Best-Small-and-Medium-Companies-to-Work-For-LST_KQ0,43.htm

The final list is compiled using Glassdoor’s proprietary algorithm, led by its Economic Research Team, and takes into account quantity, quality and consistency of reviews. Complete awards methodology can be found here: https://www.glassdoor.com/Award/index.htm

pMD is always on the lookout for smart, talented, and driven people to join our amazing team. For more information about open positions, visit: https://www.pmd.com/careers

About Glassdoor


Glassdoor
combines all the latest jobs with millions of reviews and insights to make it easy for people everywhere to find a job and company they love. As a result, Glassdoor helps employers hire truly informed candidates at scale through effective recruiting solutions like employer branding and employee insights products. Launched in 2008, Glassdoor now has reviews and insights for more than 1.3 million companies located in more than 190 countries. For more information, visit glassdoor.com.

Copyright © 2008-2020, Glassdoor, Inc. “Glassdoor” and logo are proprietary trademarks of Glassdoor, Inc.

About pMD

pMD was founded more than 20 years ago with the mission to reduce medical errors and save patient lives, and have developed a set of products and services to support this mission. pMD’s HIPAA-compliant software arms health care professionals with powerful, intuitive mobile tools that improve patient care. With pMD’s secure communication, telehealth, and data capture platforms, health care teams finally have an elegant and simple technology to maximize efficiency and collaboration, capturing everything right at the point of care. pMD interfaces with all major electronic medical records, hospital systems, and medical billing systems, enabling the efficient sharing of data and cutting down on medical errors. pMD is committed to developing the best solution and providing superior customer service. For more information, contact pMD or visit www.pmd.com.

Media Contacts

pMD:
Ari Brosowsky
PR Manager
[email protected]

Glassdoor:
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/72677b5a-9525-47f8-b968-45b091191acb

RESTON, Va., Jan. 13, 2021 (GLOBE NEWSWIRE) — Lightbridge Corporation (NASDAQ: LTBR), an advanced nuclear fuel technology company, today announced that Seth Grae, President & Chief Executive Officer of Lightbridge Corporation, will participate in a panel discussion on Nuclear Beyond Power: Hydrogen, Heat, and Desalination at the prestigious 2021 Atlantic Council Global Energy Forum on Wednesday, January 20, 2021, at 10:00 a.m. Abu Dhabi time (1 a.m. ET). The Forum will be livestreamed on the Atlantic Council’s YouTube page, at https://www.youtube.com/channel/UCw0y9zO1RXI6uEzoKbbnxTQ

The Atlantic Council Global Energy Forum is the premiere international gathering of government, industry, and thought leaders to set the energy agenda for the year. Now in its fifth year, the Forum, which has previously been held in person in Abu Dhabi, has emerged as the go-to energy conference to discuss the geopolitical and market issues confronting the energy industry in the coming year, develop new partnerships, and demonstrate thought leadership on global energy trends. The 2021 Forum will have a special focus on the post-pandemic energy system, emerging net-zero carbon goals, the role of the Middle East in the energy transition, and US energy and foreign policy priorities in the Biden administration.

To learn more about the 2021 Atlantic Council Global Energy Forum and to register, please visit https://www.atlanticcouncil.org/programs/global-energy-center/global-energy-forum/

About Lightbridge Corporation

Lightbridge (NASDAQ: LTBR) is an advanced nuclear fuel technology development company based in Reston, Virginia, United States. The Company is developing Lightbridge Fuel™, a proprietary next-generation nuclear fuel technology for current and future reactors, which significantly enhances the economics, safety, and proliferation resistance of nuclear power. Lightbridge invented, patented, and has independently validated its technology, with goals of preventing climate change and enhancing national security. The Company has assembled a world-class development team. Four large electric utilities that generate about half of America’s nuclear power advise Lightbridge on fuel development and deployment. The Company plans to operate under a licensing and royalty model and based on the increased power generated by Lightbridge-designed fuel, expects to offer high ROI for operators of existing and new reactors. For more information please visit: www.ltbridge.com.

To receive Lightbridge Corporation updates via e-mail, subscribe at

https://www.ltbridge.com/investors/news-events/email-alerts

Lightbridge is on Twitter. Sign up to follow @LightbridgeCorp at http://twitter.com/lightbridgecorp.

Forward Looking Statements

With the exception of historical matters, the matters discussed in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the timing and outcome of research and development activities, other steps to commercialize Lightbridge Fuel™ and future governmental support and funding for nuclear energy. These statements are based on current expectations on the date of this news release and involve a number of risks and uncertainties that may cause actual results to differ significantly from such estimates. The risks include, but are not limited to:
the Company’s ability to commercialize its nuclear fuel technology; the degree of market adoption of the Company’s product and service offerings; market competition; dependence on strategic partners; demand for fuel for nuclear reactors; the Company’s ability to manage its business effectively in a rapidly evolving market;
changes in the political environment; risks associated with the further spread of COVID-19, including the ultimate impact of COVID-19 on people, economies, and the Company’s ability to access capital markets; the outcome of the arbitration with the Company’s former joint venture partner and dissolution of the Enfission joint venture; as well as other factors described in Lightbridge’s filings with the U.S. Securities and Exchange Commission. Lightbridge does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise, except as required by law. Readers are cautioned not to put undue reliance on forward-looking statements.

A further description of risks and uncertainties can be found in Lightbridge’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at http://www.sec.gov/ and www.ltbridge.com.

Investor Relations Contact:

Matthew Abenante, IRC
Director of Investor Relations
Tel: +1 (646) 828-8710
[email protected]

With So Many Remarkable Submissions This Year, The Rising Star Award Has Been Created to Recognize Five Additional
Black Student Leaders That Represent The Next Wave of Legacy Makers

LOS ANGELES, Jan. 13, 2021 (GLOBE NEWSWIRE) — The Legacy Lab, Team One’s award-winning think tank and strategic consultancy, has announced the recipient of its second-annual Legacy Lab Foundation Scholarship. Launched in 2019, the unique scholarship seeks to champion tomorrow’s leaders working toward progress today. And for the first time, five additional extraordinary students will be recognized with the Rising Star Award.

Over a hundred submissions were received from Black and African-American students at 74 schools across the country, including several of the top ranked Historically Black Colleges and Universities (HBCUs). Given the overwhelming response and many accomplished participants, the judging panel ultimately decided to expand the program this year, awarding not just one $10,000 scholarship, but five additional awards.

Responses flooded in from students across a wide range of majors and fields of studies, all articulating what legacy meant to them. From those studying to be teachers to educate the next generation to finance majors working toward diversifying their sector to future doctors and nurses on a mission to democratize healthcare access to theatre majors working to change the way audiences relate to minority groups. Each recipient articulated a clear, specific long-term contribution in their respective field, and demonstrated impressive promise, already making strides toward achieving their intended impact.

This year, the $10,000 scholarship was awarded to Gianna White, a Sustainable Urban Environments undergraduate at New York University. In the long-term, Gianna hopes to “help build more sustainable cities and make sure no one is left behind in the process” and intends to go into research and design for the public transportation sector after she graduates. She is currently the co-director of NYU Urban Food Lab, a vertical farming research team that hosts community education programs, fosters discussions on food justice, and recently received a grant from the EPA to research composting plastics and the impact that microplastics have on food.

The five Rising Star Awards were granted to Alaysia Barker-Vaughn, a Political Science major and African American Studies minor undergraduate at Loyola Marymount University who is working to help other students within the foster care system achieve higher education and intends to run for local office in her hometown of Pasadena, CA; N’maya Bryant, a MBA Candidate at Florida A&M University who is working toward solving the wealth and opportunity gap in our country and is currently spearheading a financial literacy project; Deveraux Mackey, a Finance undergraduate at Howard University who is helping to create more business opportunities for women and people of color; Jennie Nwokoye, a Systems Engineering Management graduate student from Georgetown University who is on a mission to make good and affordable primary healthcare ubiquitous to vulnerable populations in Nigeria; Marie Chantal Nyirahategekimana, a Chemical Engineering undergraduate at Howard University who is working toward solving the refugee crisis.

“Not only were we blown away by the response this year, we were amazed by the significant contribution these young leaders are already making in their fields of study. These aren’t just idealists, these students are already making an impact and putting their ideas out into the world,” said Mark Miller, Chief Strategy Officer at Team One and Founder of The Legacy Lab. “As we reflect back on a year filled with hardship and demand for societal change, the mission of The Legacy Lab Foundation and the pivotal role of the next generation is abundantly clear. This group of remarkable students gives us hope for a brighter future ahead.”

This scholarship is granted by The Legacy Lab Foundation, a nonprofit part of Team One’s Legacy Lab, created to invest in leaders and organizations aiming to make a durable difference in the world. It is inspired by the ambitious founders, co-founders and re-founders highlighted in The Legacy Lab’s first book, “Legacy in the Making: Building a Long-Term Brand to Stand Out in a Short-Term World.” (McGraw Hill Education). And it is powered by The Giving Back Fund, an LA-based nonprofit that facilitates charitable giving.

In 2019, The Legacy Lab Foundation awarded its first student-focused scholarship. The inaugural Legacy Lab Scholar, Isabelle Hall, is a recent graduate from the University of Southern California with an M.S. in Social Entrepreneurship.

For more information on The Legacy Lab Foundation Scholarship, head to: https://www.givingback.org/legacy-lab-scholarship/. The next call for entries will be announced in Fall 2021.

ABOUT TEAM ONE

Team One is Publicis Groupe’s fully integrated media, digital and communications agency dedicated to helping premium brands thrive in the modern media landscape. Team One has five North American offices, including its Los Angeles headquarters, Dallas, New York, Chicago and Atlanta. Team One clients include Lexus, The Ritz-Carlton Hotel Company, Expedia, Jacuzzi Brands, St. Regis Hotels and Resorts, Ste. Michelle Wine Estates, Make-a-Wish, Gateway for Cancer Research, and Cathay Pacific. Visit



TeamOne-USA.com



.

ABOUT THE LEGACY LAB

Launched in 2012, The Legacy Lab is a Los Angeles-based think tank exploring the dynamics of long-term brand building in a short-term world. It focuses on ambitious leaders—remarkable men and women who have succeeded in making their brands enduringly unique, inspiring and influential—even as the times, technology and competition change around them. The Legacy Lab includes The Legacy Lab
Consultancy, which helps brands build legacies with the understanding that premium brands endure over time and have lasting value, as well as The Legacy Lab Foundation—a nonprofit created to invest in leaders and organizations aiming to make a durable difference in the world. The Legacy Lab is an enterprise of Team One. For more information, visit thelegacylab.com and follow all the latest learning on Twitter @thelegacylab and on Facebook @



www.facebook.com/thelegacylab



.

MEDIA CONTACT:

Christine Perez

DiGennaro Communications

[email protected]

212 966 9525

1. Global customer consensus on Saphyr’s capability to identify actionable variants in hematological malignancies detected by several cytogenomic methods combined

2. Saphyr identifies additional variants missed by traditional methods that have prognostic and therapeutic value, with a faster turn-around time and lower cost

3. KU Leuven Hospitals, Belgium, is implementing a Saphyr-based assay they developed for routine diagnostic use in Acute Lymphoblastic Leukemias in their clinic, replacing or reducing significantly the number of traditional cytogenomic tests
   

SAN DIEGO, Jan. 13, 2021 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) announced that day two of its five-day Next-Generation Cytogenomics Symposium featured eight Saphyr users presenting their results and experiences using the Saphyr® system for optical genome mapping (OGM) to analyze the genomes of patients with heme malignancies. The presentations by scientists and clinicians from leading hospitals and medical research institutions in Europe, the US and China discussed results on a variety of blood cancers, including Myelodysplastic Syndromes and a number of acute and chronic leukemias, and all 8 studies showed that Saphyr-based analyses of hematological malignancies can identify actionable variants detected by several cytogenomic methods combined, find additional important variants missed by traditional methods with prognostic and therapeutic value, and can do so with a shorter turn-around time and at a lower cost.

Dr. Tuomo Mantere, University of Oulu, Finland and Radboud University Medical Center, the Netherlands presented an update on published work evaluating OGM for the analysis of 52 patient samples with a variety of forms of leukemia. Saphyr showed 100% concordance with previous findings from the 3 standard cytogenetic methods of karyotyping, fluorescent in-situ hybridization (FISH) and chromosomal microarray (CMA) combined for simple cases. In complex cases it finds more complexity than standard methods could, and more closely represents the actual structure of the cancer genome than current methods.

Dr. Blanca Espinet and Dr. Anna Puiggros, Hospital del Mar in Barcelona, Spain presented their study on Chronic Lymphocytic Leukemia (CLL), comparing Saphyr results on 10 non-complex and 12 complex CLL samples against Cytoscan HD and karyotype. Early conclusions for the study show that Saphyr detected most of the previously known abnormalities but provided additional structural information and detected many additional genomic abnormalities, making it a valuable tool to assess genomic complexity. 

Dr. Gordana Raca, Director of the Clinical Cytogenomics Laboratory, Children’s Hospital Los Angeles presented on a pilot study on pediatric Acute Lymphocytic Leukemia (B-ALL) comparing the performance of OGM against standard testing. She presented the actionable finding of a druggable gene fusion that was missed by standard methods and not identified by their custom gene panel, since it was not expected in B-ALL, illustrating the importance of genome-wide, unbiased structural variation (SV) detection as provided by Saphyr. In half of the studied samples Saphyr identified complex rearrangements entirely missed by standard cytogenetics because karyotyping requires cells to be cultured. Karyotyping therefore can show a skewed picture of the genome since cancer cells often don’t grow well in culture and only the cells that do are analyzed. Saphyr doesn’t require culturing, and thus shows the true state of the cancer genome. Dr. Raca concluded that Saphyr showed important results for research applications and for the clinic, that it was able to detect a large number of variants that were missed by karyotyping and that it can identify the mechanisms that generate cancer driving mutations. 

Dr. Rashmi Kanagal-Shamanna, Director of the Molecular Diagnostic Laboratory, MD Anderson Cancer Center presented on her work comparing OGM performance on Myelodysplastic Syndromes (MDS) against standard of care methods. She has successfully completed her previously presented pilot study on 12 samples but has since expanded the study to 50 more. She summarized that OGM with Saphyr is a single assay that detects all types of SVs, voiding the need for multiple confirmatory tests, is faster and less expensive, and has immense potential to serve as a high throughput platform for structural variant analysis.

Dr. Valentin Lestringant, CHU Amiens in France compared the performance of OGM against four existing methods in 10 ALL samples. He presented how Saphyr identified three well-described ALL rearrangements creating fusion genes that were missed by all four standard methods.

Dr. Hongxing Liu and Dr. Bo Chen, Lu Daopei Institute of Hematology, Beijing, China presented their analysis with Saphyr of 14 acute leukemias and compared with results from karyotyping, multiplex PCR and RNA-seq. Saphyr identified a total of 10 fusion genes including one never before identified fusion. Of the 10 identified by OGM, 4 were missed by PCR and 5 missed by karyotyping. They concluded that OGM is a powerful tool for SV detection because it has high throughput, high resolution and high accuracy, and unlike PCR-based assays for fusion detection it is unbiased and genome wide.

Barbara Dewaele, PhD, Supervisor of the Laboratory for Genetics of Hematological Malignancies at KU Leuven in Belgium presented on 10 B-ALL and 10 T-ALL samples analyzed with OGM. Their current clinical workflow requires them to run up to 12 tests successively, which is costly, laborious and takes up to 4 weeks. She concluded that Saphyr provided informative results in each case, had no false positives, and identified all known translocations with a turn-around time of just one week. Additionally, Saphyr identified several important variants that were missed by all other methods.

Based on the results of this study, the KU Leuven hospital is implementing the Saphyr-based assay they developed for the routine diagnosis of B-ALL and T-ALL in their clinic immediately, replacing their multiplex ligation-dependent probe amplification (MLPA) assay entirely, reducing the number of most FISH tests ran on each sample to zero or one, and similarly reducing PCR based tests. They plan to expand its use to AML and CLL leukemias in the near future.

Brynn Levy, PhD, FACMG, Director of the Clinical Cytogenetics Laboratory at Columbia University, presented on the national multicenter evaluation of Saphyr in Acute Myeloid Leukemia, representing a consortium that includes the most important cancer research and treatment centers in the US. The previously reported and published study compared OGM results on 100 AML samples against karyotype, FISH and CMA. Dr. Levy concluded that OGM is concordant with all three traditional cytogenomics tools combined, and provides additional clinically useful information, missed by traditional methods, in 11% of the cases, and better characterizes the identified events in 40% of patients. Saphyr improves on genome analysis for AML patients by combining 3 assays in one, represents a significant time and cost saving, and provides a more objective, automated analysis that would remove subjective testing decisions at individual sites and could potentially remove disparity in healthcare.

The symposium continues throughout the week. The full schedule of speakers and registration access is available at http://bit.ly/3pLPT28

About Bionano Genomics

Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit www.bionanogenomics.com or www.lineagen.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the timing and content of the presentations identified in this press release; the effectiveness and utility of Bionano’s technology in basic genetic research and clinical settings, and in the contexts and applications contemplated by the presentations identified in this press release; adoption of Saphyr as a standard platform in research and pathology settings; and the execution of Bionano’s strategy. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACTS

Company Contact:

Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
[email protected]

Investor Relations Contact:

Ashley R. Robinson
LifeSci Advisors, LLC
+1 (617) 430-7577
[email protected]

Media Contact:

Darren Opland, PhD
LifeSci Communications
+1 (617) 733-7668
[email protected] 

IRVINE, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported preliminary unaudited fourth quarter 2020 revenue.

Preliminary Fourth Quarter Revenue and Business Highlights:

• Preliminary unaudited revenue is expected to be in the range of $47.9 million to $48.9 million in the fourth quarter of 2020, a 141% to 146% increase over the prior year period and 24% to 26% increase over the third quarter of 2020.
• The company completed approximately 4,600 procedures in the fourth quarter, a 156% increase over the prior year period and a 24% increase over the third quarter of 2020.

“We are pleased with our procedural growth in the fourth quarter and the opportunity to save and transform the lives of VTE patients, especially in the face of the challenges presented by the pandemic,” said Bill Hoffman, Chief Executive Officer of Inari Medical. “Our team is executing our strategic plan and we look forward to sharing our progress on our quarterly earnings call.”

The preliminary unaudited revenue results described in this press release are estimates only and subject to revision until we report our full financial results for 2020 in our Annual Report on Form 10-K.

About Inari Medical, Inc.

Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA for the treatment of pulmonary embolism and clot in transit in the right atrium.

Forward Looking Statements

Statements in this press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements include estimates regarding fourth quarter revenue and total procedures and the potential impact of COVID-19 on the business, and are based on Inari’s current expectations, forecasts and assumptions, are subject to inherent uncertainties, risks and assumptions that are difficult to predict and actual outcomes and results could differ materially due to a number of factors. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Quarterly Report on Form 10-Q for the period ended September 30, 2020 and in its other reports filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are based on information available to Inari as of the date hereof and are made only as of the date of this release. Inari undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing Inari’s views as of any date subsequent to the date of this press release. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Inari.

Investor Contact:

Westwicke Partners
Caroline Corner
Phone +1-415-202-5678
[email protected]

Serendipity Survey by Bromwich+Smith shows pandemic positives can prevail

TORONTO, Jan. 13, 2021 (GLOBE NEWSWIRE) — As the country braces for a winter of continued lockdowns and an uncertain year ahead, a new national survey focuses on some much-needed positives and puts to bed the idea that there is a formulaic day for sadness, known as Blue Monday. 

The Serendipity Survey by Licenced Insolvency Trustees, Bromwich+Smith, is set to counter the annual narrative of Blue Monday, which is not only based on pseudo-science (suggesting it is the most depressing day of the year) but has been under attack by its own author, who now campaigns against the idea of Blue Monday via his Twitter using the hashtag #StopBlueMonday.

The idea of Blue Monday originated in a 2005 travel company press release and has become part of the media narrative every January. But after a year of sadness and dozens of real Blue Mondays since the pandemic began, Bromwich+Smith felt it was the wrong sentiment and decided to seek out some pandemic positives through a survey of Canadians. The Serendipity Survey is being used to highlight Bromwich+Smith’s own day to counter-program Blue Monday – Hope Tuesday.  

Hope over despair: Canadians valuing life at a slower pace and being alone

In the survey, 1520 Canadians were asked, “looking back, what were some surprisingly positive consequences, if any, that came out of COVID?” and the top answer was “I’ve taken life at a slower pace.” Meanwhile, three-in-10 (29%) have re-inspired their hobbies such as cooking, reading and art, while an almost equal number have been fortunate to save money (28%). “Gained a new perspective on life” (27%) was next, followed by “[the pandemic] brought me closer to my family” (22%) and “I’ve become more comfortable being by myself” (18%). Finally, eight per cent said COVID “allowed me to reset my life or make a career change that I always feared.”

The survey provides several glimmers of hope amid any seasonal sadness or overall pandemic fatigue. While on the negative side of the ledger, one-in-four Canadians (23%) felt there were no positives to come out of COVID, the majority of Canadians have been able to glean some good.

“We cannot forget all of those who have struggled with health, lost their lives or had loved ones die as a result of COVID,” said Shawn Stack, Vice-President of Insolvency Practice, Bromwich+Smith. “The phrase ‘it’s darkest before the dawn’ is extremely apt as we tumble headfirst into our second pandemic winter, reminding us to seek hope even in the worst circumstances.”

Despite women being disproportionately impacted by the pandemic, they are still somewhat likely to put a positive spin on COVID. Here are some standout findings by gender:

• One-in-three women (32%) have been re-energized by their hobbies versus one-in-four men (24%)
• One-in-five women (20%) have become more comfortable with their own company.
• Three-in-10 men (29%) have gained a new perspective on life because of COVID compared to one-in-four women (25%)

Younger Canadians are significantly more likely to have saved money than older Canadians since the pandemic began. One-in-three (34%) 18-34-year-olds have saved money compared to one-in-four (26%) of those aged 35 and older.

Hope Tuesday and TheSerendipity Survey comes on the heels of Bromwich+Smith’s year-end study, Good Riddance 2020, that focused on renewed hope and addressed the top positive things Canadians planned to do after vaccine rollout and a normalization of life. It found people are more focused on what matters in life and what brings more meaning.

“January is a tough time and COVID restrictions are heightening people’s challenges, but there are still things to be thankful for and positive actions to carry forward into the rest of the year,” said Stack.

“Hope without a plan is a problem akin to a ship without a rudder. For folks who are dreading opening their credit card bills following the holidays, it’s important remember there are professionals for financial and debt advice who are just a phone-call away to help them restructure.”

The full results of The Serendipity Survey are available through the contacts below.  

About t
he 

Serendipity Survey

by Bromwich+Smith 

From December 18 to December 20, 2020 an online survey was conducted among a representative sample of 1,520 Canadians who are members of the Angus Reid Forum. The sample was balanced and weighted on age, gender, region and education. For comparison purposes, the sample plan would carry a margin of error of +/- 2.5 percentage points, 19 times out of 20. Discrepancies in or between totals are due to rounding.  

About Bromwich+Smith 
Bromwich+Smith, our dedicated team of Licensed Insolvency Trustees and Debt Relief Specialists are committed to rebuilding our clients’ worth, while helping relieve the overwhelming financial and emotional burden they are experiencing. Beyond our clients’ financial wellbeing, Bromwich+Smith strives to restore the personal wellbeing and self-confidence of every client. Whether it’s through a consumer proposal, bankruptcy, counselling or budgeting, our clients trust us to work with them to find customized solutions to make them whole again. With offices in BC, Alberta, Saskatchewan and Ontario, Bromwich+Smith helps thousands of Canadians each year rebuild their worth. Bromwich+Smith’s Debt Relief Specialists are available for an initial consultation by phone at 1-855-884-9243 or via www.bromwichandsmith.com. 

For further information: To arrange an interview with Shawn Stack, Vice President at Browmich+Smith, please contact: 

Dana Sharman 
MAVERICK Public Relations 
[email protected] 
1-705-878-6493 

Kim Jackson 
Public Relations Specialist 
Bromwich+Smith 
[email protected] 
1-403-801-0242 

Webinar to review expanded biomarker data from the company’s Phase 1b clinical trial of XPro1595 targeting neuroinflammation in patients with Alzheimer’s disease

LA JOLLA, Calif, Jan. 13, 2021 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that the company will host a Key Opinion Leader (KOL) webinar on Thursday, January 21, from 8:00 AM – 9:00 AM Eastern Time.

The webinar will present new biomarker data from the company’s Phase 1b trial of its lead clinical candidate, XPro1595, in patients with Alzheimer’s disease (AD) and biomarkers of inflammation. The primary goal of this 12 week trial is to demonstrate that XPro1595 decreases neuroinflammation. The Company will present expanded biomarker results in patients treated with XPro1595 for at least 12 weeks. 

“We previously reported that XPro1595 decreased neuroinflammation in AD patients as measured by white matter free water (WMFW), a novel biomarker of inflammation that can be measured non-invasively by MRI,” stated CJ Barnum PhD, Head of Neurosciences at INmune Bio. “Consistent with our approach to study a small number of patients intensively in early phase studies, this updated data set will report on additional measures that support our primary goal of reducing neuroinflammation and address some of the exploratory biomarkers that relate to neurodegenerative disease.”

Webinar participants include:

• RJ Tesi, M.D., co-founder and Chief Executive Officer of INmune Bio.
• Dr. CJ Barnum, Ph.D., Head of Neuroscience at INmune Bio.
• Dr. Judith Jaeger Ph.D., President and Principal Scientist of CognitionMetrics, LLC. Dr. Jaeger is a cognitive neuropsychologist and internationally recognized expert in assessing cognitive endpoints.
• Dr. Malú Gámez Tansey, Ph.D., Director, Center for Translational Research in Neurodegenerative Disease, Medical College of the University of Florida. Dr. Malu Tansey is an internationally recognized expert in neuroinflammation and neurodegenerative disease, including AD. Of note, Malu is an inventor of XPro’s DN-TNF technology and has been studying the drug’s effects on neuroinflammation for over 20 years.

RJ Tesi, M.D., co-founder and CEO of INmune Bio, stated: “We look forward to presenting updated data from this important trial with XPro1595.  Our goal is to give investors and clinical experts the information they need to understand the role of XPro1595 in treating neuroinflammation in patients with AD.”

KOL Discussion Call Information

To participate in this event, you must register in advance. Please click on the link below.  After registering, you will receive a confirmation email containing information about joining the webinar.

To register and access the live webinar click here

Date: January 21, 2021
Time: 8:00 AM Eastern Time

About XPro1595

XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that acts differently than currently existing TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro1595 could have substantial beneficial effects in patients with Alzheimer’s disease by decreasing neuroinflammation. For more information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit this section of the INmune Bio’s website.

About INmune Bio, Inc.

INmune Bio, Inc
. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s and Treatment Resistant Depression (XPro1595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.

Information about Forward-Looking Statements

Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, Quellor™, XPro1595, LIVNate™, and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contact:

David Moss, CFO
(858) 964-3720
[email protected]

Investor Contact:

Chuck Padala
LifeSci Advisors
(646) 627-8390
[email protected]

Media Contact:

Meredith Sosulski, Ph.D.
LifeSci Communications
(929) 469-3851
[email protected]

NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) — Better Choice Company (OTCQX: BTTR) (“Better Choice”) (the “Company”), an animal health and wellness company, today announced the appointment of Donald Young as the Company’s new Executive Vice President of Sales, effective January 1, 2021.

Donald Young joins The Better Choice Company with more than 29 years of experience leading the sales organizations of several prominent pet specialty pet food brands including The Nutro Company (Natural Choice, MAX, and Greenies Brands) and Merrick Pet Care, Inc. (Merrick, Backcountry, Purrfect Bistro and Fresh Kisses Brands).

Following his success at The Nutro Company, Mr. Young led the turnaround and expansion of Merrick Pet Care’s Pet Specialty business from 2010 – 2020, where he was directly responsible for growing the company from a niche brand to the #3 natural player in the pet specialty retail channel. Merrick Pet Care more than quadrupled its sales during this period, surpassing $500m in the process and ultimately leading to the sale of Merrick Pet Care to the Nestle Purina Company. Donald has also been recognized by his peers in the Pet Industry for his track record of success, winning numerous sales awards throughout his career including recognition as one of Pet Age Magazine’s 2019 ICON Winners.

Scott Lerner, CEO of The Better Choice Company stated, “We are incredibly excited for Donald to join our team. We are looking forward to having him build upon his past successes to help drive the growth and expansion of Better Choice’s brands in the Pet Specialty channel.”

Donald Young stated, “I have been incredibly impressed by the caliber of the team Better Choice has assembled and am excited to hit the ground running and build on the momentum already created. I am committed to building a world-class sales team that is empowered to do what is right for our retail partners so we can all succeed together. Whether that be investments in education and services or simply delivering the best possible product for pet parents.”

Michael Young, Chairman of the Better Choice Company, added, “Attracting talent like Donald Young speaks to the quality of the platform Better Choice has built and continues to build. We continue to add world-class industry experts, as we execute on our goal to build the most dynamic team in the animal health and wellness industry. With the recent additions to our team as well as recent announcements to the changes in our capital structure, Better Choice is extremely well positioned to capitalize on the major macro-economic trends in the industry. Donald will be centrally located in Nashville, TN where we just announced a re-positioning of our fulfillment and distribution centers.”

About Better Choice Company, Inc.

Better Choice Company Inc. is a growing animal health and wellness company committed to leading the industry shift toward pet products and services that help dogs and cats live healthier, happier and longer lives. We take an alternative, nutrition-based approach to animal health relative to conventional dog and cat food offerings and position our portfolio of brands to benefit from the mainstream trends of growing pet humanization and consumer focus on health and wellness. We have a demonstrated, multi-decade track record of success selling trusted animal health and wellness products and leverage our established digital footprint to provide pet parents with the knowledge to make informed decisions about their pet’s health. We sell the majority of our dog food, cat food and treats under the Halo and TruDog brands, which are focused, respectively, on providing sustainably sourced kibble and canned food derived from real whole meat, and minimally processed raw-diet dog food and treats. For more information, please visit https://www.betterchoicecompany.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. The Company has based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Some or all of the results anticipated by these forward-looking statements may not be achieved. Further information on the Company’s risk factors is contained in our filings with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:

Better Choice Company, Inc.
Scott Lerner, CEO

Investor Contact:

KCSA Strategic Communications
Valter Pinto, Managing Director
PH: 212-896-1254
[email protected]

WASHINGTON, Jan. 13, 2021 (GLOBE NEWSWIRE) — In the first non-employment lawsuit ever filed against the U.S. Securities and Exchange Commission (“SEC”) by a past employee, Jordan A. Thomas today filed a lawsuit against the Commission in the United States District Court for the District of Columbia. The suit seeks to vacate illegal rule changes that undermine the integrity and effectiveness of the SEC Whistleblower Program—a program that he had a leadership role in developing.

On September 23, 2020, in a 3-2 vote, the Commission approved new rules for its whistleblower program. A broad coalition of SEC Commissioners and anticorruption organizations, along with a bipartisan group of Congressmen, including Senators Warren and Grassley, publicly opposed the proposed rule changes on legal and policy grounds. Thomas, now a partner and Chair of the Whistleblower Representation Practice at the law firm of Labaton Sucharow, seeks to reverse this controversial rulemaking.

“Over the last decade, the SEC has made few missteps with its successful whistleblower program, but this was a major step backwards,” said Thomas. “In a rare legal trifecta, the new whistleblower rules simultaneously violate the law, break faith with current SEC whistleblowers and discourage future potential whistleblowers—especially sophisticated, senior and highly-compensated ones. Christmas came early for Wall Street.”

Thomas said, “I love the SEC and do not lightly bring this lawsuit, but I feel compelled to do so. In reliance on the original whistleblower program rules, I have courageous clients who put their careers and lives on the line to assist the SEC—including wearing FBI wires and smuggling key documents out of China. Now, in the middle of the proverbial football game, the SEC has boldly claimed the authority to move the goal posts on literally hundreds of SEC whistleblowers.”

In 2011, Thomas established the nation’s first whistleblower practice exclusively focused on violations of the federal securities laws. Both pioneer and recognized leader in the field, he has been profiled in the New York Times and on NPR. His clients have secured precedent-setting whistleblower awards and have launched many of the SEC’s most high-profile cases.

To date, his clients have helped the SEC to secure over $1 billion in monetary sanctions and have won the largest single-case SEC whistleblower award in history, more than $83 million. In addition to significant monetary recoveries, among his many landmark cases, he successfully represented the first officer of a public company to win an SEC whistleblower award, the first SEC whistleblower to receive criminal immunity, and the first SEC whistleblower to receive a whistleblower award because his company retaliated against him.

Media Contact


Casie Connolly
[email protected]
(925) 451-1345

MONTRÉAL, Jan. 13, 2021 (GLOBE NEWSWIRE) — Osisko Gold Royalties Ltd (the “Corporation” or “Osisko”) (OR: TSX & NYSE) is pleased to provide the following corporate update:

PRELIMINARY Q4 2020 SALES

Osisko received approximately 18,800 attributable gold equivalent ounces¹ (“GEOs”) in the fourth quarter of 2020, for a total of approximately 66,100 GEOs in 2020, exceeding the revised guidance of 63,500 – 65,500 GEOs. These figures exclude 1,750 GEOs earned from the Renard diamond stream in the fourth quarter of 2020 from diamonds sold from inventories by the operator. The net proceeds from the Renard diamond stream were reinvested through the bridge loan with the operator of the mine.

Osisko recorded preliminary revenues² of C$64.5 million during the fourth quarter. Preliminary cost of sales², excluding depletion², was C$18.2 million resulting in a cash operating margin³ of approximately C$46.3 million. These figures include preliminary revenues² from the Renard diamond stream of C$4.3 million, costs of sales, excluding depletion², of C$1.9 million resulting in an operating cash margin of C$2.4 million.

Excluding offtakes, Osisko’s cash operating margin for royalties and streams³ was 93.5% during the fourth quarter of 2020 (97.1% excluding the Renard diamond stream).

Sandeep Singh, CEO of Osisko commented: “We are extremely pleased with the strength of our business in the fourth quarter and on having exceeded our revised guidance for the year. The upward trend in GEOs continued during the quarter and we look forward to further growth catalysts in 2021 and beyond. Further in the release, we provide an update on certain producing and development stage assets. The depth of Osisko’s portfolio is often overlooked, but we have a number of high-quality assets, at various stages of advancement, that have the potential to add significant value for shareholders.”

APPOINTMENT OF VICE PRESIDENT, INVESTOR RELATIONS

Osisko is also pleased to announce the appointment of Heather Taylor as Vice President, Investor Relations. Heather brings to the role over 15 years of capital markets experience in the metals and mining industry. Most recently, Ms. Taylor was Head of Business Development for Nexa Resources. Prior to that, she managed investor relations at Nevsun Resources until its sale. In addition, Heather brings with her a broad range of experience from former roles in institutional equity research, trading, sales and corporate development.

Sandeep Singh, CEO of Osisko commented: “I am very pleased to add Heather to our team. Her broad industry experience and network will be invaluable as we continue to execute on our corporate strategy and create long-term value for our shareholders.”

ROYALTY & STREAM PORTFOLIO UPDATE

Canadian Malartic Underground Progress

Agnico Eagle Mines Limited and Yamana Gold Inc. (together the “Partnership”) continued steady operation at the Canadian Malartic open pit.  Following exploration success at the East Gouldie, Odyssey and East Malartic zones, the Partnership announced its intent to publish a PEA study for a future underground operation in the first quarter of 2021⁴ with a target production rate of between 15,000 to 20,000⁴ tonnes per day by 2029⁴ for 400,000⁵ to 450,000⁵ gold ounces per year.  Subject to a positive construction decision, the Partnership expects to be able to begin preparation for a shaft and headframe this year and has indicated the possibility of underground mine production starting from Odyssey South as early as 2023⁴. Osisko has a 5.0% NSR royalty on the East Gouldie and Odyssey South deposits and a 3.0% NSR royalty on the Odyssey North and East Malartic deposits.

Mantos Blancos Sulphide Expansion  

Mantos Copper S.A. (“Mantos”) continued construction of the sulphide concentrator expansion at the Mantos Blancos copper mine.   The expansion is expected to increase the throughput of the operation’s sulphide concentrator plant from 4.3 Mtpa to 7.3 Mtpa by Q4 2021 and extend the life of the mine to 2035. Osisko has a stream agreement to purchase 100% of the silver produced at Mantos Blancos until 19.3 million ounces have been delivered, and 40% of the silver produced thereafter. Osisko will make ongoing payments to Mantos for each ounce of silver delivered equal to 8% of the spot price of silver. Annual deliveries of refined silver to Osisko during the first five years following commissioning of the expansion are expected to average approximately 1.2 million ounces per year.

Eagle Ramp-Up  

Victoria Gold Corp (“Victoria”) achieved commercial production at its Eagle mine in July 2020. Eagle produced 42,174 ounces of gold in Q4 2020 and is expected to continue to ramp-up production in 2021 towards a run rate of 220,000 oz per annum. Over the past several months, Victoria has also delivered excellent drill success within the broader Dublin Gulch property.   Highlight drill intercepts include: 2.77 g/t Au over 65.7 meters, 3.95 g/t Au over 19 meters, and 13.7 g/t Au over 13.7 meters at the Raven zone; and 6.14 g/t Au over 8.4 meters and a trench result of 4.65 g/t Au over a 32.0 meters at the Lynx zone.   Osisko has a 5.0% NSR royalty on the Dublin Gulch property, which includes the Eagle mine.

Éléonore Production Guidance

Newmont Corporation (“Newmont”) has provided updated guidance of 270,000 oz of gold production for the Éléonore mine in 2021, which is above its steady state objective of 250,000 oz of gold for the mine. Exploration continues on the property to enhance the life of mine profile. Osisko has a 2.0% to 3.5% NSR royalty on the Éléonore mine based on the cumulative amount of gold produced (presently 2.2% NSR royalty).

SASA Recommences Production

Central Asia Metals PLC (“CAML”) announced a resumption of lead and zinc concentrate production at the SASA mine on October 2, 2020 following a leakage at the mine’s tailings storage facility in September. CAML expects to receive a report outlining contributing factors to the leakage as well as engineering recommendations in the first quarter of this year. CAML is transitioning to cut and fill mining at SASA which should provide for higher mine recovery and reduced dilution while also leading to an increased production rate targeting 900,000 tonnes per year compared to current guidance of 825,000 to 850,000 tonnes per year. Osisko benefits from a 100% stream on silver produced at the mine with a transfer price of US$5.50 per ounce adjusted for inflation.  

Gibraltar
Continues Steady Production

Taseko Mines Ltd. (“Taseko”) continues steady operations at the Gibraltar mine while transitioning to a new operating plan which is expected to result in meaningful cost savings. After a period of cost containment in early 2020, rebounding copper prices allowed Taseko to revert to normal mining rates which started increasing in September. Osisko benefits from a stream on 75% of the payable silver produced at Gibraltar with no transfer price.

Seabee
Exploration

In the fourth quarter of 2020, SSR Mining Inc. (“SSR”) completed the successful restart of operations at the Seabee mine following a temporary shutdown related to COVID-19. SSR continues its strong history of consistent production as well as reserve replacement at the Seabee operation and in 2020 the company announced further investment in exploration at the project. 2020 exploration results include drill intercepts of 7.64 meters of 14.75 g/t Au and 2.62 meters of 28.92 g/t Au in the Santoy Gap Hanging Wall. Additionally, a new discovery was made at Batman Lake including 3.6 meters of 37.95 g/t Au. Osisko has a 3.0% NSR royalty on the Seabee mine.

Island Gold Expansion

Alamos Gold Inc. (“Alamos”) continues to expand the footprint and production potential at its Island Gold mine. A construction decision, announced in July 2020, of a shaft down to at least 1,373 meters vertical will facilitate a production increase from the current 1,200 tpd to approximately 2,000 tpd. Average annual gold production from the announced Phase III expansion project targets 236,000 ounces per year starting in 2025. The company has also intersected exceptional drill results within Osisko’s 2% NSR royalty claims, including 28.97 g/t Au over 21.76 meters and 15.38 g/t Au over 15.02 meters. Osisko has a 1.38% to 3% NSR royalty covering all of the resources and reserves at the Island Gold mine.

Lamaque Reserve Increase  

Eldorado Gold Corporation (“Eldorado”) recently announced a 12% increase in total reserves (net of depletion) at the Lamaque mine while also confirming the advancement of a new decline that will enable lower cost transport of ore to the Sigma mill and provide additional platforms for exploration of the new Ormaque discovery and Plug 4 deposits. Neither of these deposits are currently accounted for in the company’s reserve estimate and should help support Eldorado’s stated objective of increasing ore production from 1,800 tpd to 2,200 tpd by 2022. Following the expansion, Lamaque’s gold production guidance was increased to 130,000 – 140,000 oz of gold in 2021, ramping up to 145,000 – 155,000 oz of gold in 2023. Near-term, Eldorado expects to release the results of a study assessing the potential for an additional mill upgrade up to 5,000 tpd further increasing the potential at Lamaque. Osisko has a 1.0% NSR royalty on the Lamaque mine.

Bald Mountain Production Increasing on NSR Ground

Kinross Gold Corp (“Kinross”) announced expansion of production in the northern sector of its Bald Mountain property in 2023 and 2024 where Osisko has a 4% GSR royalty on the Royale deposit and a portion of North Duke as well as a 1% GSR royalty on the Winrock deposit and a portion of the Saga deposit. Bald Mountain produced 187,961 oz of gold in 2019 resulting in 466 GEOs to Osisko as mining was carried out largely outside Osisko’s royalty ground.

Pan and Gold Rock

Fiore Gold Ltd. (“Fiore”) completed an exploration program in 2020 totaling 21,741 meters and announced an updated reserve, resource and life of mine plan that extended the Pan mine life by two years into 2025. The company announced production guidance of 44,000 to 47,000 ounces of gold in 2021. Fiore also completed a PEA study on its Gold Rock project in the spring of 2020 and has since initiated a program of resource expansion, metallurgical, geotechnical and condemnation drilling in support of a feasibility study targeted for completion in 2H21. First drill results were announced subsequent to year-end, headlined by 48.8 meters of 2.17 g/t gold and 32.0 meters of 1.41 g/t gold. Osisko has a 4% NSR royalty on the Pan property and a 2% to 4% NSR royalty on portions of the Gold Rock property.

Renard Restart

The Renard diamond mine, operated by Stornoway Diamonds Canada Inc. (“Stornoway”), restarted operations in September 2020 following an extended care and maintenance period related to COVID-19. Stornoway’s focus has been on cost reduction while the diamond market recovers. In the fourth quarter of 2020, Stornoway conducted two sales. In the first sale the company sold 203,491 carats at an average price per carat of US$70.66 and in the second sale the company sold 253,842 carats at a price of US$79.70 per carat, a significant improvement over pre-COVID pricing levels. Stornoway’s cost reductions, coupled with strengthening diamond prices resulted in positive cash generation from Renard and no additional drawdowns on the company’s working capital facility. Osisko has a 9.6% diamond stream on the Renard mine but has agreed to defer payments from the stream until April 2022. Payments can be made prior to this date if the financial situation of Stornoway permits. Osisko also holds a 35.1% equity interest in Stornoway.

Cariboo

Osisko completed the spin-out of Osisko Development Corp. (“ODV”) on November 25, 2020, which included, among other things, Osisko transferring the Cariboo gold project to ODV. In 2021, ODV is expected to begin small-scale production at the Bonanza Ledge Phase II (“BL2”) deposit targeting approximately 62,000 ounces of gold over an initial two-year mine life. While production advances at BL2, ODV will be progressing a feasibility study on the broader Cariboo project which is expected to be released in the second half of 2021. ODV is fully-financed to reach a construction decision at Cariboo with an initial design targeting over 200,000 ounces of annual gold production with ramp-up beginning in 2023. Osisko retains 77.9% of the common equity in ODV plus a 5% NSR royalty on the entire Cariboo property.

San Antonio

San Antonio, located in Sonora Mexico, is ODV’s other principal asset with an initial resource estimate containing 27.6 million tonnes grading 1.18 g/t Au for 1 million ounces of gold in the inferred resource category. While ODV plans a comprehensive drill program to delineate further upside at the project, the company is currently targeting initial production of 50,000 to 70,000 ounces of gold with additional near-term potential from a gold stockpile beginning in 2021. ODV believes that San Antonio is a scalable, heap leach gold operation with considerable exploration upside. Osisko has a 15% gold and silver stream at San Antonio with a transfer payment equal to 15% of the spot gold and silver price.

Windfall Exploration Results

Osisko Mining Inc. (“Osisko Mining”) released an updated resource estimate on February 19, 2020 for its Windfall project including 4.1 million tonnes at 9.1 g/t Au for 1.2 million ounces of gold in the indicated resource category and 14.5 million tonnes at 8.4 g/t Au for 3.9 million ounces of gold in the inferred resource category. Since that release, approximately 250,000 metres of new drilling has been completed, focused on infill and expansion of the known mineralized zones and extensions to the Underdog and Triple 8 zones, which has provided strong indications for further discovery at depth. The pace of drilling increased throughout last year, with over 30 surface and underground drills currently on site, including 8 underground drills focused on the Lynx infill program. Osisko Mining continues to advance an exploration ramp towards Triple Lynx for the next planned bulk sample. Drill intersections continued to impress in 2020; and included a record intercept of 2 meters of 13,634 g/t Au and 28 meters of 202 g/t Au in the Lynx deposit, both uncut with true widths estimated at 55% to 80% of core length. The company expects to publish a feasibility study for Windfall in the first half of 2022. The Corporation has a 2% to 3% NSR royalty on the Windfall deposit, and also owns 14.5% of outstanding shares of Osisko Mining.

Horne 5

Falco Resources Ltd. (“Falco”) is advancing permitting work at Horne 5 located in Québec, which is one of the largest undeveloped gold projects in Canada. Falco made progress in its discussions with stakeholders in 2020, entering into copper and zinc offtake agreements and a C$10 million convertible debenture with Glencore Canada Corporation which owns and operates the adjacent Horne copper smelter in Rouyn-Noranda. Osisko owns a 90% to 100% silver stream on Horne 5 with a transfer payment of 20% of the spot silver price up to a maximum of US$6.00/oz. Osisko has a remaining C$115 million milestone-based funding obligation for the 90% silver stream and a further option to increase the stream percentage to 100%.

Ermitaño Nearing Production

First Majestic Silver Corp. (“First Majestic”) progressed its development of the Ermitaño mine, located in Sonora, Mexico, that is expected to displace approximately 40% of mill feed to the company’s 3,000 tpd Santa Elena processing plant. Mineralization has been intersected by underground mine development and First Majestic is currently planning five separate mining levels. Three drills were operating on the 102,000 hectare property in Q4 2020 and a prefeasibility study is expected in the first quarter of this year with first ore targeted for mid-year. Osisko has 2% NSR royalty on the Ermitaño property.

Santana Construction

Minera Alamos Inc. (“Minera Alamos”) is fully funded for the completion of construction of its Santana heap leach gold project in Sonora, Mexico following a C$15 million bought deal financing completed in September 2020. Mining is expected to commence in the first quarter of 2021 and Minera Alamos has guided to initial production of 25,000 to 30,000 ounces of gold per annum. The company is also completing its Phase-3 exploration efforts targeting district potential of one to two million ounces of gold. Osisko has a 3.0% NSR royalty on the Santana project.

Fortuna Permits Received

Minera Alamos has obtained all key federal permits for the construction and development of its Fortuna project located in Durango, Mexico. Fortuna is slated to be the company’s second mine following construction at Santana. A 2018 PEA study on Fortuna outlined a robust operation producing approximately 50,000 gold-equivalent ounces annually. Osisko has the right to purchase a 4% NSR royalty on Fortuna for C$9 million.

Back Forty Permitting Delays

In 2020, Aquila Resources Inc. (“Aquila”) advanced its Back Forty project in Michigan, publishing a positive PEA study in September and submitting its Dam Safety Permit application in November. The PEA, which incorporated underground resources into the mine plan, extended the life of mine to 12 years and outlined opportunities to further increase gold recoveries. On January 4, 2021, Aquila announced that a Michigan judge had overturned the Back Forty Wetlands Permit on the basis that the company’s groundwater model did not provide a reliable identification of the wetland impacts. The company is evaluating its alternatives which include submitting an updated permit application or appealing the court’s decision. Osisko retains an 18.5% gold stream and an 85% silver stream on Back Forty, subject to transfer payments equal to 30% of the spot gold price and US$4.00 per ounce of silver, respectively.

Amulsar

On July 6, 2020, Lydian International Corp. (“Lydian”) completed a plan of arrangement with its secured creditors, including Osisko, as part of its corporate restructuring and winding up of the company. Construction at Lydian’s Amulsar project in Armenia was approximately 75% complete when illegal blockades restricted the company’s access to the project. Amulsar contains 119.3 million tonnes of 0.74g/t yielding 2.83 million ounces of Proven and Probable gold reserves. Osisko is working closely with its partners and the government of Armenia to restart construction of the project. Osisko holds approximately 36% indirect equity interest in the project, an 81.91% gold offtake, a 4.22% gold stream and a 62.5% silver stream on the project, subject to transfer payments equal to US$400/oz and US$4.00/oz respectively.

Cerro Del Gallo Permitting

Argonaut Gold Inc. (“Argonaut”) is expected to make a construction decision this year at the open pit, heap leach Cerro Del Gallo project, located in Guanajuato Mexico. This follows a prefeasibility study published in December 2019 which outlined 77,000 oz of gold-equivalent production annually for a 15 year mine life. Cerro Del Gallo is advancing through the permitting process. Osisko has a 3% NSR royalty on a portion of the Cerro Del Gallo property which currently hosts proven and probable reserves of 91.8 million tonnes at 0.56g/t Au for 1.64 million ounces of gold.

Magino Underground Exploration

Argonaut has begun readying construction of its Magino open pit mine project, located in Ontario Canada, for which first gold is expected in early 2023. On January 4, 2021 the company announced that it had executed a fixed bid engineering, procurement, construction and commissioning contract with Ausenco Engineering Canada Inc. A small portion of the eastern limit of the proposed Magino pit is covered by a claim upon which Osisko retains a 3% NSR royalty. Drilling below the pit has resulted in the discovery of high grade mineralization, a more significant part of which falls within Osisko’s royalty claims. This mineralization occurs along the same trend as Alamos Gold’s Island mine which is among the highest-grade gold mines in Canada. Argonaut is expected to continue drilling in 2021, including on the claims upon which Osisko has a royalty. Select drill results covered by Osisko’s royalty include: 12.4 meters grading 10.6 g/t Au and 9 meters grading 13.4 g/t; intervals are uncapped and estimated true thickness is 8.7 meters and 6.3 meters respectively.

Ambler Feasibility Study

Trilogy Metals Inc. (“Trilogy”) released a feasibility study at its Ambler project, located in Alaska on August 20, 2020. The study outlines a large open pit mine project with average annual production of 155 million pounds of copper, 192 million pounds of zinc, 32 million pounds of lead, 32,000 ounces of gold and 3.4 million ounces of silver over a 12 year mine life. The project is a joint venture between Trilogy and South32 Limited. Trilogy is currently focused on the submission of the federal 404 permit in the second half of 2021. Osisko has a 1% NSR royalty on the property that is subject to a US$10M buyback option in favour of Trilogy.

Hermosa PFS in Progress

On May 12 2020, South32 Limited (“South32”) published a maiden resource on for the Clark deposit at Hermosa, located in Arizona. The resource statement outlined 33 million tonnes of 2.49% Zn, 9.39% Mn and 56 g/t Ag in the indicated category and 22 million tonnes of 2.04% Zn, 8.64% Mn and 110g/t Ag in the inferred category. South32 is advancing an integrated mine plan of the Taylor and Clark deposits with a pre-feasibility study expected in the second half of 2021.   Osisko has a 1% NSR royalty covering the Hermosa property.

Pine Point

Osisko Metals Inc. (“Osisko Metals”) continues to identify new mineralization and confirm the mineral inventory described in the 2020 PEA of the Pine Point project in NWT, Canada. The current mineral resource estimate, amenable to open pit mining methods, consists of 12.9 million tonnes grading 6.29% ZnEq in the indicated mineral resource category and 37.6 million tonnes grading 6.80% ZnEq in the inferred mineral resource category. The company is conducting exploration activities to follow up on high priority targets while permitting advances. In the fourth quarter 2020, Osisko increased its NSR royalty on the Pine Point property from 1.5% to 2.0%. Osisko also owns 17.4% of the common shares of Osisko Metals.

Kirkland Lake / Upper Beaver

Agnico Eagle Mines Limited (“Agnico”) acquired a 50% interest in the Kirkland Lake project from Yamana in December of 2017 for C$162.5 million. In 2020, Agnico planned to drill 48,000 meters on the project which sits within a 25,506 hectare land package. The current mineral inventory includes 8 million tonnes at 5.43 g/t Au for 1.4 million ounces of probable gold reserves, 16 million tonnes at 3.2 g/t Au for 1.7 million ounces of indicated gold resources and 30.7 million tonnes at 3.34 g/t Au for 4 million ounces of inferred gold resources. Agnico is expected to provide an updated open pit and underground resource estimate and economic study in 2021. Osisko has a 2% NSR royalty on the Kirkland Lake property.

Hammond Reef

Agnico has received environmental approvals for the Hammond Reef project in Ontario and is evaluating potential mining scenarios including ore sorting. The pit-constrained mineral resource at Hammond Reef currently sits at 208 million tonnes grading 0.67 g/t Au for 4.5 million ounces of gold in the Measured and Indicated resource categories. In January 2020, the company exercised its first right of refusal to repurchase a 2% NSR royalty on Hammond Reef from Kinross Gold for US$12 million. Osisko has a 2% NSR royalty on the Hammond Reef Project.

Bralorne Drilling

Talisker Resources Ltd. (“Talisker”) is in the process of completing a 23,000 meter drill program at the historic Bralorne mine site in south-central British Columbia, where it owns over 297,000 hectares of mineral claims. The company is well funded for its 2021 exploration campaign and expects to expand drilling at the brownfield site, testing mineralization around old underground workings. Historic mining at Bralorne has produced over 4.2 million ounces of gold at an average grade of 17.7 g/t. Osisko owns a 1.2% NSR royalty on the Bralorne project and 7.4% of the common equity of Talisker.

Antakori Drilling

In October 2020, as part of a strategic partnership entered into with Regulus Resources Inc. (“Regulus”), Osisko purchased a royalty on the Antakori project which is located adjacent the large Tantahuatay and Cerro Corona copper-gold mines in Peru. Regulus continues to release results from its 25,000 meter drill program and on January 7, 2021 the company announced an extension of the mineralized footprint of the project. While Regulus expects to continue releasing exploration results at Antakori, drilling on the Anta Norte target was recently paused to address certain community concerns about potential impacts of their drilling activities. Osisko owns a 1.5% to 3% NSR royalty covering approximately 75% of the indicated resources and 50% of the inferred resources at Antakori.

Sable Resources

On October 13, 2020, Osisko elected to exercise its option to increase its royalty on the properties owned and generated by Sable Resources Ltd. (“Sable”) from 1% to 2%. Following the transaction with Osisko, Sable closed the sale of one of its properties, the Margarita silver project located in Chihuahua Mexico, to Magna Gold Corp. (“Magna”). Osisko expects that Sable’s ability to discover and advance high-quality exploration-stage projects should generate additional opportunities for Osisko to surface royalties as was the case with the Magna transaction. In addition to the 2% NSR Osisko owns on the properties owned and generated by Sable, Osisko owns 9.9% of the common equity of the company.

Marban PEA

O3 Mining Inc. (“O3”) filed a preliminary economic assessment for the Marban project located in Malartic, Québec, outlining a conventional open pit mine averaging 115,000 ounces of annual gold production for 15 years. O3 has also commenced an extensive exploration campaign on the Marban and Alpha properties with up to 12 drills in operation in the first quarter of 2021. Osisko has a 0.5% to 2% NSR on the Marban property.

Casino

Western Copper and Gold (“Western Copper”) plans to complete an optimized PEA for its Casino copper-gold project, located in Yukon Canada. The resource estimate for Casino was updated in 2020 to include 2,390 million tonnes of 0.14% Cu and 0.19 g/t Au in the measured and indicated resource categories, plus 1,461 million tonnes of 0.1% Cu and 0.14 g/t Au in the inferred resource category. In anticipation of positive outcomes from the PEA, Western Copper is developing a plan for engineering, field investigations, test work, permitting and community relations activities to support the development of a feasibility study for the project and recently conducted a C$28.75 million equity financing. Osisko owns a 2.75% NSR royalty on the Casino project.

Wharekirauponga (WKP)

In July of 2020, OceanaGold Corp. (“Oceana”) published results from a PEA demonstrating encouraging results for the WKP project, located in New Zealand. With only 35,000 meters of drilling on WKP, Oceana was able to define 3.5 million tonnes grading 9.2 g/t Au for 1 million ounces of gold. Exploration activities targeting expansion of the mineral inventory restarted in second half of 2020. Osisko has a 2% NSR royalty on the WKP property.

Notes:

Osisko has included certain performance measures in this press release that do not have any standardized meaning prescribed by International Financial Reporting Standards (IFRS) including (i) attributable gold equivalent ounces and (ii) cash operating margin. The presentation of these non-IFRS measures is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. As Osisko’s operations are primarily focused on precious metals, the Corporation presents attributable GEOs and cash operating margins as it believes that certain investors use this information to evaluate the Corporation’s performance in comparison to other mining companies in the precious metals mining industry who present results on a similar basis. However, other companies may calculate these non-IFRS measures differently. Note that these figures have not been audited and are subject to change. 

1. GEOs are calculated on a quarterly basis and include royalties, streams and offtakes. Silver earned from royalty and stream agreements are converted to gold equivalent ounces by multiplying the silver ounces by the average silver price for the period and dividing by the average gold price for the period. Diamonds, other metals and cash royalties are converted into gold equivalent ounces by dividing the associated revenue by the average gold price for the period. Offtake agreements are converted using the financial settlement equivalent divided by the average gold price for the period.
2. These figures have not been audited and are subject to change. As the Corporation has not yet finished its quarter-end close procedures, the anticipated financial information presented in this press release is preliminary, subject to final quarter-end closing adjustments, and may change materially. The figures presented include revenues and cost of sales from the Renard diamond stream.
3. Cash operating margin (in dollars) represents revenues less cost of sales, excluding depletion (C$64.5 million – C$18.2 million = C$46.3 million). Cash operating margin on revenues and streams (in percentage) represents the cash operating margin earned from revenues and streams (in dollars) divided by revenues earned from royalties and streams ([C$48.8 million – C$3.2 million] / C$48.8 million = 93.5%).
4. Yamana Gold Inc. Corporate Presentation dated December 18, 2020
5. Peter Marrone, Executive Chairman of Yamana Gold Inc. at the Gold Canaccord Genuity Val d’Or Day Virtual Webcast on December 8, 2020

Qualified Person

The scientific and technical content of this news release has been reviewed and approved by Guy Desharnais Ph.D., P.Geo, Vice President Project Evaluation for Osisko Royalties, who is a “qualified person” for purposes of NI 43-101. Details of the various mineral inventory and exploration results can be found on the websites of the respective companies. Unless otherwise noted drill results are of unknown true thickness due to early stage of exploration, and grades are uncapped.

About Osisko Gold Royalties Ltd

Osisko Gold Royalties Ltd is an intermediate precious metal royalty company focused on the Americas that commenced activities in June 2014. Osisko holds a North American focused portfolio of over 135 royalties, streams and precious metal offtakes. Osisko’s portfolio is anchored by its cornerstone asset, a 5% net smelter return royalty on the Canadian Malartic mine.

Osisko’s head office is located at 1100 Avenue des Canadiens-de Montréal, Suite 300, Montréal, Québec, H3B 2S2.

For further information, please contact Osisko Gold Royalties Ltd:

Heather Taylor
Vice President, Investor Relations
Tel. (514) 940-0670 #105
[email protected]

Forward-looking Statements

Certain statements contained in this press release may be deemed “forward
‐
looking statements” within the meaning of applicable Canadian and U.S. securities laws. These forward
‐
looking statements, by their nature, require Osisko to make certain assumptions and necessarily involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward
‐
looking statements. Forward
‐
looking statements are not guarantees of performance.  These forward
‐
looking statements, may involve, but are not limited to, statements with respect to future events or future performance, the realization of the anticipated benefits deriving from Osisko’s investments, the general performance of the assets of Osisko, and the results of development exploration and production activities as well as expansions projects relating to the properties in which Osisko holds a royalty, stream or other interest. Words such as “may”, “will”, “would”, “could”, “expect”, “believe”, “plan”, “anticipate”, “intend”, “estimate”, “continue”, or the negative or comparable terminology, as well as terms usually used in the future and the conditional, are intended to identify forward
‐
looking statements. Information contained in forward
‐
looking statements is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including, without limitation, management’s perceptions of historical trends; current conditions; expected future developments; the ongoing operation of the properties in which Osisko holds a royalty, stream or other interest by the operators of such properties in a manner consistent with past practice; the accuracy of public statements and disclosures made by the operators of such underlying properties; no material adverse change in the market price of the commodities that underlie the asset portfolio; no adverse development in respect of any significant property in which Osisko holds a royalty, stream or other interest; the accuracy of publicly disclosed expectations for the development of underlying properties that are not yet in production; and the absence of any other factors that could cause actions, events or results to differ from those anticipated, estimated or intended. Osisko considers its assumptions to be reasonable based on information currently available, but cautions the reader that their assumptions regarding future events, many of which are beyond the control of Osisko, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect Osisko and its business. Such risks and uncertainties include, among others, that the financial information presented in this press release is preliminary and could be subject to adjustments, the successful continuation of mining activities in Québec and more particularly of the operations underlying the Corporation’s assets, the performance of the assets of Osisko, the growth and the benefits deriving from its portfolio of investments, risks related to the operators of the properties in which Osisko holds a royalty, stream or other interest, including changes in the ownership and control of such operators; risks related to development, permitting, infrastructure, operating or technical difficulties on any of the properties in which Osisko holds a royalty, stream or other interest, the influence of macroeconomic developments as well as the impact of and the responses of relevant governments to the COVID-19 outbreak and the effectiveness of such responses.

For additional information with respect to these and other factors and assumptions underlying the forward
‐
looking statements made in this press release, see the section entitled “Risk Factors” in the most recent Annual Information Form of Osisko which is filed with the Canadian securities commissions and available electronically under Osisko’s issuer profile on SEDAR at www.sedar.com and with the U.S. Securities and Exchange Commission and available electronically under Osisko’s issuer profile on EDGAR at www.sec.gov. The forward
‐
 looking statements set forth herein reflect Osisko’s expectations as at the date of this press release and are subject to change after such date. Osisko disclaims any intention or obligation to update or revise any forward
‐
looking statements, whether as a result of new information, future events or otherwise, other than as required by law.